GleamWall
中文EN

MREO Mereo BioPharma Group plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1719714 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY35.2%
TTM EPS YoY40.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-76.6%
ROA-64.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets19.8%
Debt / equity0.00x
Current ratio5.22x
Interest coverage-440.64x

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$800,000$0—$0$0$500,000—$0
R&D expense$2.09M$1.81M$4.75M$4.19M$4.27M$5.37M$3.93M$8.82M
SG&A expense$4.93M$5.22M$4.02M$4.20M$6.04M$5.49M$7.27M$6.45M
Operating income-$6.22M-$7.03M-$8.77M-$8.39M-$10.02M-$10.50M-$11.20M-$15.28M
Interest expense$10,000$16,000$20,000$23,000$28,000$24,000$180,000$375,000
Pretax income-$5.86M-$7.00M-$6.72M-$7.35M-$7.02M-$14.62M-$12.89M-$7.05M
Income tax$0$0$0$0$0$0$0$0
Net income-$5.86M-$7.00M-$6.72M-$7.35M-$7.02M-$14.62M-$12.89M-$7.05M
EBITDA-$6.19M-$6.99M-$8.72M-$8.35M-$9.98M-$10.46M-$11.16M-$15.24M
EPS (basic)-0.01-0.01-0.01—-0.01-0.02-0.02—
EPS (diluted)-0.01-0.01-0.01—-0.01-0.02-0.02—
Weighted avg. shares (diluted)804.53M803.56M801.81M—799.95M799.44M784.28M—
Balance sheet
Cash & equivalents$26.10M$30.12M$30.10M$40.99M$48.70M$56.12M$62.48M$69.80M
Current assets$28.67M$33.40M$40.03M$45.02M$52.41M$61.42M$66.90M$74.76M
PP&E, net$24,000$54,000$91,000$137,000$174,000$218,000$247,000$257,000
Intangibles$129,000$256,000$381,000$516,000$643,000$470,000$554,000$643,000
Total assets$29.58M$34.71M$40.61M$45.92M$53.60M$62.63M$68.32M$76.39M
Current liabilities$5.49M$5.68M$6.18M$4.30M$6.02M$7.56M$7.50M$13.85M
Total liabilities$5.87M$6.06M$6.56M$5.00M$7.00M$8.45M$8.24M$15.42M
Shareholders' equity$23.71M$28.65M$34.05M$40.92M$46.60M$54.18M$60.08M$60.97M
Cash flow statement
Operating cash flow-$4.05M-$6.04M-$4.31M-$7.68M-$7.31M-$7.65M-$8.33M-$9.42M
Capital expenditure$0$0$0$0$0$0$20,000$0
Free cash flow-$4.05M-$6.04M-$4.31M-$7.68M-$7.31M-$7.65M-$8.35M-$9.42M
Investing cash flow$0$0-$300,000$0$300,000$0-$320,000$0
Financing cash flow$0$0$0$39,000$0-$134,000$422,000-$40,000
Depreciation & amortization$30,000$38,000$44,000$36,000$39,000$44,000$38,000$38,000
Stock-based compensation$909,000$1.32M$1.60M$1.54M$1.71M$2.06M$2.28M$1.51M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.